According to Alnylam Pharmaceuticals latest financial reports the total debt is $1.26B, an decrease of -1.13% to 2022. At the end of 2022 company had $1.28B total debt. This figure represents the debts and financial obligations that Alnylam Pharmaceuticals combine short-term debt, long-term debt, and other fixed payment obligations (such as capital leases) of a business that are incurred while under normal operating cycles.
Year | Total debt | Change |
---|---|---|
2023 | $1.26B | -1.13% |
2022 | $1.28B | 33.57% |
2021 | $957.04M | 97.61% |
2020 | $484.32M | 75.39% |
2019 | $276.13M | 820.45% |
2018 | $30.00M | - |